Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14859175 | 0.88 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8738720 | 0.88 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL3527402 | 0.83 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1756375 | 0.83 | CA12 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30469443 | 0.83 | CA12 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4022762 | 0.82 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| Hydrochloric Acid SCHEMBL21711861 | 0.81 | CA12 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30208191 | 0.80 | CES2 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL4208340 | 0.80 | CES2 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2173855 | 0.80 | CA12 (0.53) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605404-B | Novel thiazole-containing compound, intermediate and application thereof | 合肥美诺医药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-114605404-A | Novel thiazole-containing compound, intermediate and application thereof | 苏州美诺医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-1443963-B1 | ANTIBODY TARGETING COMPOUNDS | SCRIPPS RESEARCH INST (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8252902-B2 | Complexing antigen, antibodies; immunoassay | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2428226-A1 | Antibody targeting compounds | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | KYOTO UNIVERSITY (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | KYOTO UNIVERSITY (JP) | 2011-05-19 | — | — | US | disclosed |
| US-7090828-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-6818201-B2 | FOR ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; USEFUL FOR IMAGING ATHEROSCLEROSIS, RESTENOSIS, CARDIAC ISCHEMIA AND MYOCARDIAL REPERFUSION INJURY; THERAPY OF RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-16 | — | — | US | disclosed |
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6558649-B1 | Benzodiazepine nonpeptide targeting moiety bound to chelating group; diagnosis and treatment of cancer; imaging tumors; monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-6548663-B1 | Imaging tumors and cancer with radioisotope benzodiazepine metal complex as contrast agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | EPCAM, HDGF, DSC1 | GABRA1 3279/4885GABRG2 3093/4885GABRB3 3931/4885 |
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | GABRA1 853/4885GABRG2 1311/4885GABRB3 1771/4885 |
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | GABRA1 2662/4885GABRG2 3028/4885GABRB3 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.